Illumion, a University of Cambridge spinout developing advanced battery imaging technology, has secured £1.7 million in a funding round co-led by Foresight Group and ZEISS Ventures, with participation from Parkwalk, Cambridge Enterprise Ventures, Cambridge Angels and YourVC.
52North, a University of Cambridge spin-out behind the Aster™ biomarker platform, has clinched £3.2 million to accelerate its push to help transform urgent cancer care and bring its core product, Neutrocheck® to market.
Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufacturing. Under the two-year memorandum of understanding (MoU), the companies will validate Atelerix’s alginate hydrogel encapsulation technology for preserving biological samples during microgravity research missions, improving sample quality and reducing payload mass and associated costs.
British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures.
The UK cleantech business Nova Pangaea Technologies has agreed to collaborate with NorSAF, the company behind the Baltic’s largest Sustainable Aviation Fuel (SAF) project, to develop an advanced ethanol production plant in Latvia to supply the new facility.
CPI Enterprises and EverQuest Capital Partners have co-invested alongside Parkwalk Advisors and EMV Capital in a £1.6 million funding round for Cambridge-based biotechnology company Qkine, underscoring their shared commitment to backing high-potential UK life sciences businesses developing innovative technologies with global commercial impact.
Digital mental health company Psyomics has appointed experienced US healthcare executive Raj Malik to its Board as the business grows in the UK and focuses on international expansion.
Cambridge company Foventa Therapeutics, a clinical-stage ophthalmology business, is embarking on a Series A round to fund exciting technology after changing its name from Exonate.